Jump to main content.

Contact Us

Health & Environmental Research Online (HERO)

You are here: EPA Home Research NCEA HERO Anti-vRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2

Please wait while we submit your request.
This may take several minutes...


1045339 
Journal Article 
Anti-vRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2 
Sakagami, Y; Komemushi, S; Tsukamoto, G; Kondo, H; Yoshikawa, A; Muraoka, O 
2008 
No 
Biocontrol Science
ISSN: 1342-4815 
13 
103-109 
English 
Anti-VRE and anti-MRSA activities of new quinolone derivatives [The two quinolone derivatives are 8- [3-[(ethylamino) methyl]-1-pyrrodinyl] -7-fluoro-9, 1-[(N-methylimino)methano]-5-oxo-5H-thiazolo[3,2-a]quinolone-4-carboxylic acid (compound A) and 7-fluoro-8-morpholino-9,1-[(N-methylimino) methanol-5-oxo-5H-thiazolo [3,2-a] quinolone-4-carboxylic acid (compound B)] and their synergism with commercial antibiotics were investigated. Compound A exhibited potent antibacterial activity against VRE and MRSA among the five new quinolone compounds tested, and showed superior activity to pefloxacin, ofloxacin and levofloxacin, which are clinically in use these days. With respect to the anti-VRE activity, compound A showed synergism with fosfomycin (FOM), and partial synergism with ampicillin (ABPC), gentaicin (GM), minocycline (MINO) and vancomycin hydrochloride (VCM). Partial synergism in anti-VRE activity was also observed between compound B and GM, MINO, FOM and VCM. Compound A also showed synergism with MINO and FOM in anti-MASA activity. Partial synergism was observed with ABPC, GM and VCM. Synergism with ABPC was not detected in anti-MRSA activity. On the other hand, the synergism of compound B with FOM, and the partial synergisms with ABPC, GM and MINO were also found against MRSA. No synergism with ABPC was found against MRSA. These results suggested that compound A and B could possibly reduce the daily administration dose of these antibiotics in the treatment of nosocomial infections, and also reduce the possibility of the occurrence of nosocomial infections caused by VRE and/or MRSA. 
antibacterial activity; new quinolones; VRE; MRSA; synergism 
IRIS
• Methanol (Non-Cancer)
     Search 2012
          WOS
          ProQuest
 
Anti-Bacterial Agents 
Drug Synergism 
Enterococcus 
Methicillin Resistance 
Microbial Sensitivity Tests 
Quinolones 
Staphylococcus aureus 
Vancomycin Resistance 
 

Jump to main content.

page loading graphic